Clinical Studies

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. More than 300 patients have participated in clinical studies at the Cancer Center over the past five years.

For More information on clinical studies, contact Beth Ann Brundage, RN, OCN, at (518) 926-6644 or Nannette Oberhelman, at (518) 926-6701.

Clinical Trials: Breast

CTSU A011106

  • ALTERNATE: Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment in Postmenopausal Women: A Phase III Stud

CTSU NRG-BR003

  • Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer


Clinical Trials: Head and Neck

CTSU RTOG 0920

  • A Phase III Study of Postoperative Radiation Therapy (IMRT) =/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer


Clinical Trials: Lung

CTSU EAY131 (MATCH)

  • Molecular Analysis for Therapy Choice; Screening for Treatment Assignment Based on Genetic Testing

CTSU S1400

  • A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer - Lung Map Study

SCLC Limited

C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

NSCLC Limited

CTSU A151216 NSCLC

  • Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512

  • A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU EA5142

  • Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ALCHEMIST)

CTSU A081105 Alchemist

  • A Phase III Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC (ALCHEMIST)

P D5160L00032- RADIANCE:

  • Resistance & Activating Mutations DIAgnosed Among NSCLC, Community Dwelling EGFR Mutation Positive Patients; Open Label Non-randomized Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients with NSCLC

Clinical Trials: Pancreatic

CTSU RTOG-0848

  • A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of PancreasAdenocarcinoma


Clinical Trials: Prevention

CTSU S0820

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers s/p one year after primary resection in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Rare Tumors

CTSU S1609

  • DART Study: Dual Anti-CTLA-4 and Anit-PD-1 Blockade in Rare Tumors

Clinical Trials: Rectal

CTSU N1048

  • A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Registries:

P Registry

  • Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

P Registry

  • informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia